News & Insights
Courtney Barnes represents Feldman Legal Advisors at International Conference on Psychedelic Research
Feldman Legal Advisors’ Courtney Barnes represented the firm in the Netherlands at the International Conference on Psychedelic Research where she reconnected with some of the U.S.’s most influential thought leaders in psychedelic policy and science and met numerous creatives and researchers pushing the movement forward across the pond.
California Drug Policy Reformers Return to Ballot Measure Campaigns After Governor Newsom Vetoes Psychedelics Decriminalization Bill
California Governor Gavin Newsom has vetoed Senate Bill 58, the first psychedelics decriminalization measure to pass both chambers of a state legislature. Now, California drug policy reformers are refocusing their efforts on ballot measure campaigns for 2024.
Understanding the FDA’s New Guidelines for Psychedelic Drug Development and Research
The Food and Drug Administration (FDA) released draft guidance for researchers to consider when conducting clinical trials of the therapeutic benefits of psychedelic drugs.
5 Tips to a Successful “Distressed” Cannabis/Psychedelics Acquisition
Whether players in the cannabis and psychedelics industries like it or not, the era of acquisitions of troubled or struggling companies is here. Access to capital, the mother’s milk of these industries, has been severely restricted for over a year. As losses continue, debt matures and defaults grow, businesses seek strategic alternatives including M&A.
Australia Authorizes Therapeutic Access to MDMA and Psilocybin
On February 3, 2023, Australia’s Therapeutic Goods Administration (ATGA), a medical authority under the Department of Health and Aged Care, announced a change to the country’s regulatory classification of psilocybin and methylenedioxymethamphetamine (MDMA), allowing the compounds to be prescribed by psychiatrists for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), respectively. The decision was made after the government determined that there was sufficient medical and scientific evidence to support the conclusion that the substances will be beneficial for these conditions. This dramatic change makes Australia the first major country to legalize the therapeutic use of these substances.
